tyrosinaemia
Metabolic · 2015–2023
No submission for this condition has carried consumer input, including the 11 made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| amino acid formula with vitamins and minerals, without phenylalanine and tyrosine and supplemented with arachidonic acid and docosahexaenoic acid Dietary management of tyrosinaemia in infants and young children from 6 months to 5 years of age. | Mar 2023 | Recommended with restriction | none received |
| glycomacropeptide and essential amino acids with vitamins and minerals Treatment of tyrosinaemia (TYR). The submission concerned a reformulation of an existing PBS-listed product. | Mar 2023 | Recommended | none received |
| amino acid formula with vitamins and minerals without phenylalanine and tyrosine Dietary management of tyrosinaemia. | Jul 2020 | Recommended | none received |
| glycomacropeptide and essential amino acids with vitamins and minerals Dietary management of tyrosinaemia in children and adults. | Jul 2020 | Recommended with restriction | none received |
| glycomacropeptide and essential amino acids with vitamins and minerals Dietary management of tyrosinaemia. | Jul 2019 | Recommended with restriction | none received |
| amino acid formula with fat, carbohydrate without phenylalanine and tyrosine Dietary management of tyrosinaemia (TYR). | Nov 2019 | Recommended with restriction | none received |
| amino acid formula with vitamins and minerals without phenylalanine and tyrosine Dietary management of tyrosinaemia. | Mar 2017 | Recommended with restriction | none received |
| glycomacropeptide and essential amino acids with vitamins and minerals Dietary management of tyrosinaemia. | Nov 2017 | Recommended with restriction | none received |
| amino acid formula with vitamins and minerals without phenylalanine and tyrosine Tyrosinaemia. Oral liquid powder formulation containing 15 g protein equivalent per 34 g bottle. | Jul 2016 | Recommended with restriction | none received |
| glycomacropeptide and essential amino acids with vitamins and minerals Treatment of tyrosinaemia in adults and children over one year of age. | Jul 2015 | Recommended with restriction | none received |
| amino acid formula with vitamins and minerals Nutritional management of phenylketonuria (PKU), tyrosinaemia (TYR), and maple syrup urine disease (MSUD) in children. | Mar 2015 | Recommended | no section in document |
What the PBS pays
$83M in government benefit over 2024–25, across 77,226 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| amino acid formula with vitamins and minerals, without phenylalanine and tyrosine, supplemented with arachidonic acid and docosahexaenoic acid | $19.4M |
| Amino acid formula with vitamins and minerals (three formulations: without phenylalanine; without phenylalanine and tyrosine; without valine, leucine and isoleucine) | $17.2M |
| amino acid formula with vitamins and minerals without phenylalanine and tyrosine | $17M |
| glycomacropeptide and essential amino acids with vitamins and minerals | $16.6M |
| amino acid formula with fat, carbohydrate without phenylalanine and tyrosine | $12.6M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 11 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.